section name header

Pronunciation

sal-ME-te-role

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: adrenergics

Indications

REMS


Action

  • Produces accumulation of cyclic adenosine monophosphate at beta2-adrenergic receptors.
  • Relatively specific for beta2 (pulmonary) receptors.
Therapeutic effects:
  • Bronchodilation.

Pharmacokinetics

Absorption: Minimal systemic absorption follows inhalation.

Distribution: Action is primarily local.

Metabolism/Excretion: Metabolized in the liver via the CYP3A4 isoenzyme; 60% excreted in feces, 25% excreted in urine.

Half-Life: 3–4 hr.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
Inhaln10–25 min3–4 hr12 hr



9 hr in adolescents.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: palpitations, tachycardia

GI: abdominal pain, diarrhea, nausea

MS: muscle cramps/soreness

Neuro: headache, nervousness, tremor

Resp: cough, paradoxical bronchospasm

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Asthma

Prevention of Exercise-Induced Bronchospasm

COPD

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Serevent Diskus